Hematopoietic SCT (HSCT) is a well-recognized therapeutic procedure to prolong life and cure patients with lifethreatening hematological malignancies; however, the risk of developing secondary carcinoma may increase in longterm survivors. The objective of this study was to determine the incidence and risk factors for secondary squamous carcinoma after HSCT. Between 1984 and 2004, 170 allogeneic HSCT recipients aged 415 years, who had survived for 45 years were enrolled. Demographic data and the characteristics of secondary carcinoma were collected and analyzed for the determination of the incidence and risk of developing secondary carcinoma. Eight patients developed secondary carcinoma, including five oral squamous cell carcinomas, one esophageal, one gastric and one ovarian carcinoma, but no cutaneous carcinomas were detected at a median follow-up of 14.1 years (range, 5.1-23.3 years) after HSCT. The accrual 10-year cumulative incidence of secondary carcinoma was 2.89%. In univariate and multivariate analyses, chronic GVHD and age 440 years at the time of HSCT were both significant risk factors independently associated with the development of secondary carcinoma. Thus, the occurrence of secondary carcinoma is one of the late complications in patients undergoing HSCT. Oral squamous cell carcinoma was more common in our patients after HSCT, indicating the need for lifelong surveillance of the oral cavity. Moreover, because of the relatively long latency in developing secondary carcinoma, extended follow-up is required for a thorough understanding of the incidence and characteristics of secondary carcinoma after HSCT.
Introduction
Hematopoietic SCT (HSCT) is widely used to treat patients with hematological diseases. The improvement in survival after HSCT has drawn increased attention to late complications during long-term survival, such as pulmonary dysfunction and secondary malignancies. [1] [2] [3] Secondary malignancies are well-recognized, important complications in patients with hematological diseases after HSCT. Since early 1990, a series of studies reported that the most common secondary malignancies, including leukemia, lymphomas and solid tumors, occurred in patients undergoing HSCT, especially patients after allo-SCT. [2] [3] [4] [5] [6] The time course and relative risk of developing secondary malignancies after HSCT differ as a function of disease categories; specifically, most lymphomas, such as post transplantation lymphoproliferative disease, occur within the first few months after HSCT, 7, 8 whereas solid tumors and leukemia are generally diagnosed years after the HSCT is performed. [2] [3] [4] [5] [6] Therefore, improvement in survival after HSCT has resulted in a need to assess issues related to long-term complications of secondary malignancies.
The occurrence of secondary malignancies has been attributed to the cumulative toxicity of previous chemotherapy, radiotherapy and immunosuppressive agents. Risk factors include age at the time of HSCT, development of GVHD and prolonged immunosuppressive therapy. 2, [5] [6] [7] 9 Immunological alterations may predispose patients to squamous cell carcinoma of the buccal cavity, particular in view of the association between oral mucositis and chronic GVHD (cGVHD). 9 The purpose of this study was to undertake a retrospective analysis of long-term follow-up after HSCT to determine the incidence, risk factors and treatment outcomes of patients who developed secondary carcinoma.
Patients and methods

Study population
Between 1984 and 2004, a total of 668 patients received HSCT at the Bone Marrow Transplantation Unit of Taipei Veterans General Hospital. Among these patients, 219 patients received autogeneic HSCT and the other 449 patients received allogeneic HSCT. A total of 170 patients were reviewed, all of whom were 415 years of age and had a follow-up of 45 years after high-dose chemotherapy and allogeneic HSCT. Patient characteristics are shown in Table 1 . The male-to-female ratio was 1.36:1, with a median age of 31 years (range, 15-68 years). The distribution of hematological disorders was as follows: AML (n ¼ 50), acute lymphocytic leukemia (n ¼ 20), chronic myelocytic leukemia (n ¼ 51), non-Hodgkin's lymphoma (n ¼ 11) and severe aplastic anemia (n ¼ 38).
The initial 42 patients with AML, chronic myelocytic leukemia, acute lymphocytic leukemia and lymphoma were conditioned with 120 mg/kg CY, followed by TBI with 12-13.2 Gy. Among these patients, no patient received a reduced-intensity conditioning regimen. Subsequent patients with AML and chronic myelocytic leukemia received CY (120 mg/kg) and BU (16 mg/kg). A total of 38 patients with severe aplastic anemia were treated with 200 mg/kg of CY and 3 Gy of TBI.
Between 1984 and 1997, the HLA typing method used was a microlymphocyte cytotoxicity test. 10 After 1997, the HLA typing method used was a PCR with sequencespecific primers.
11 Among these 170 patients, 151 patients had sibling donors and 19 patients had unrelated donors. All patients had six completely matched alleles compared with their donors, expect one patient who had one mismatched allele.
The immunosuppression regimen for allogeneic BMT included both MTX and CsA given after transplantation. A dose of 15 mg/m 2 of MTX was administered i.v. on day 1 and 10 mg/m 2 of MTX was administered i.v. on days 3, 6 and 11. The administration of CsA (1.5 mg/kg i.v. or 6.25 mg/kg orally every 12 h) was started a day before marrow infusion and continued until day 50 after HSCT. The dose was then decreased by 5% weekly until 6 months after transplantation if the patients were devoid of manifestations of acute or cGVHD. For patients with GVHD, azathioprine and steroids were administered until the disease was controlled.
Immunohistochemistry
For oral human papillomavirus infection (HPV) detection, tissue sections were baked in a 70 1C oven for 30 min and dewaxed, hydrated and treated with PBS containing 3% hydrogen dioxide. The citrate buffer epitope retrieval method was used to retrieve the Ag at 99 1C. The tissue sections were then incubated with the anti-HPV-16 E6 Ab (1:100 dilution; Produktionsvej 42, DK-2600; Dako Denmark A/S, Glostrup, Denmark) for 25 min at room temperature. Polymer (biotin; Dako Denmark A/S), the secondary Ab, was added for 10 min at room temperature, and then the sections were incubated in 3,3'-diaminobenzidine peroxidase substrate solution for 10 min. The signal was developed in 3,3'-diaminobenzidine H 2 O 2 solution. The slides were counterstained with hematoxylin for 5 s.
Serological tests for viral infection
Hepatitis B surface Ag (HbsAg) was detected using a microparticle enzyme immunoassay (IMx-Abbott Laboratories, Abbott Park, IL, USA), and the reactivity of HBsAg was calculated from the ratio of the sample rate to the MODE 1 calibrator rate. Abs to the hepatitis C virus (HCV) were also detected using a microparticle enzyme immunoassay (Abbott IMxHCV version 3.0; IMx-Abbott Table 1 Baseline characteristics of 170 patients who were 415 years of age with at least a follow-up of X5 years after high-dose chemotherapy and allogeneic HSCT
Characteristic
No. of patients (%)
Age ( Laboratories). In our study, we defined patients with positive HBsAg as having hepatitis B virus (HBV) infection; patients with Ab to HCV were regarded as having an HCV infection.
Statistical analysis
All statistical analyses were performed using the Statistical Package of Social Sciences 13.0 software (SPSS Inc, Chicago, IL, USA). A P-value o0.05 was considered to be statistically significant. The Kaplan-Meier estimate was used for estimating the cumulative incidence rates of developing a secondary carcinoma, and the log-rank test was selected for identifying the risk factors of a secondary carcinoma (univariate analysis). To test the independent predictive effect of variables that showed significance in separated analysis by log-rank test, the Cox's proportional hazards model was applied (multivariate analysis) for variables with a P-value o0.1 in the log-rank test.
Results
Secondary carcinoma
The disease characteristics and outcomes for HSCT patients with secondary carcinoma are shown in In eight patients with secondary carcinoma, seven patients had cGVHD after HSCT and three patients' ages were 440 years at the time of HSCT (Table 2 ). Habits and symptoms for patients with oral squamous cell carcinoma Cigarette smoking, alcohol consumption and betel nut chewing habits were reviewed in the five patients who developed oral squamous cell carcinoma. Two males with AML, but no females, had a history of cigarette smoking for 8 and 10 years before treatment of the disease, as shown in Table 2 . None of the patients had a history of betel nut chewing. Before developing oral squamous cell carcinoma, all five patients had oral cGVHD and used immunosuppressants for prolonged periods of time. Symptoms and signs of recurrent oral ulcers, warts and white patches over the buccal cavity, lip or tongue, were noted from 2 months to 5 years with a median follow-up of 1 year.
Results of HPV immunohistochemistry staining
Tissue samples from patients with cervical intraepithelial lesion 3, which were positive for papillomavirus by immunohistochemistry, were used as positive controls. All the samples from the five patients with oral squamous cell carcinoma stained negative for immunohistochemistry. The results are shown in Figure 2 .
Results of HBV and HCV infection
The HBV (P ¼ 0.1951) and HCV (P ¼ 0.0985) virus infection were NS risk factors for developing secondary carcinomas (Table 3) . Among the eight patients with secondary carcinoma, one patient had HBV infection, one patient had HCV infection and two patients had both HBV and HCV infections at the same time (Table 2 ).
Follow-up of patients with secondary carcinoma Of our eight patients with secondary carcinoma, seven patients (87.5%) remain alive and free from disease, one (12.5%) is alive but has had disease recurrence. Five patients with oral squamous cell carcinoma received wide or total excision and two patients received adjuvant concurrent chemoradiotherapy. One patient had local recurrence 3 years after surgery and received photodynamic therapy.
Discussion
Hematopoietic SCT is an effective treatment for both malignant and nonmalignant hematological diseases. The progress in treatment and supportive care has translated into steady improvement of survival for patients with HSCT. As the number of long-term survivors has increased, the late complications of the procedure have drawn the attention of transplantation specialists. Secondary malignancies have an important role in late nonrelapse mortality and impact on the quality of life.
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The incidence of developing secondary solid tumors is 2-6% in patients at 10 years after allo-SCT. 2 On the basis of the Center for International Blood and Marrow Transplant Research and the Seattle group involving 28 874 patients, 12 the risk of developing secondary solid tumors is as follows, in the order of frequency: oral cavity and pharynx, bone and joint, soft tissue, liver, thyroid and brain and central nervous system. With the exception of oral cavity and thyroid carcinoma, the type of secondary solid tumors with increased risk in the other groups are sarcomas. 12 Sarcomas occur more often in patients who undergo transplantation at a younger age with irradiation during conditioning. There were no sarcoma-type malignancies occurring in our patient group, and all of our patients developed carcinoma from the epithelium. Two patients developed non-squamous cell carcinoma (SCC), including one patient with breast and the other with ovarian adenocarcinoma. Among patients who developed secondary carcinoma, one patient received TBI as conditioning for AML and two patients with severe aplastic anemia received at least 3 Gy TBI as a conditioning regimen to reduce the rate of graft failure. However, in this analysis, TBI compared with non-TBI conditioning did not have an impact on the incidence of secondary malignancies, and the result did not differ after adjusting the dose of TBI (data not shown). Adolescents and adults comprised nearly all of our patient group (age 415 years). TBI probably does not affect the patient beyond childhood with regard to the incidence of secondary malignancies; however, we do not know whether this finding applies to children. We should avoid exposure of children to radiation until clearer results are available. 12, 13 One-half of our patients with secondary carcinoma had oral squamous cell carcinoma. Among patients with primary oral SCC, cigarette smoking, alcohol consumption and betel nut chewing are well-documented risk factors. 14 HPV infection is also associated with this cancer, especially in the oropharynx. 15, 16 The role of HPV in secondary head and neck SCC after allo-SCT, however, was not clearly defined. 17 We determined the HPV status of the resected samples from our patients with secondary oral SCC, and none of the tumors showed HPV infection (Figure 2 ). In our patients with oral SCC, HPV was not associated with carcinogenesis. As a result, HPV vaccination would not benefit patients receiving HSCT in Taiwan for the prevention of oral cavity SCC. It is to be noted that Taiwan is endemic for HBV infection, with a 15% HBsAg carrier rate in the adult population. 18 Hepatitis is the most important etiology for hepatocellular carcinoma. In this study, four of eight patients with secondary malignancies were HBV and HCV carriers, including one HBV carrier, one HCV carrier and two HBV and HCV carriers. However, none of our patients developed hepatocellular carcinoma, and we did not find any association between hepatitis virus carriers and the development of secondary carcinoma. Although betel nut chewing is highly associated with oral SCC in Taiwan, 14 none of our patients chewed betel nuts. Two patients with secondary oral cavity SCC were long-term cigarette smokers before HSCT, but both of them had quit after the diagnosis of leukemia. All five patients with oral cavity SCC had oral cGVHD and used immunosuppressants for prolonged periods of time. These five patients received regular follow-up with examination of the oral cavity, and the tumors were identified in the early stages. There were no deaths attributed to the secondary oral cavity SCCs, reflecting early identification with limited-stage disease. cGVHD is an important risk factor for developing oral cavity SCC, and this finding has also been shown in other reports. 6, 9, 12 We should encourage patients who develop cGVHD, even without involvement of the oral mucosa, to check the oral cavity regularly so as to recognize oral cavity SCC at an early stage.
In our analysis, there was no correlation between the original disease and the secondary malignancies. There was also no detailed data about the donors who may have increased the risks of developing secondary oral SCC in the recipients. As a recent study showed that donor-derived BM cells may recruit to sites of chronic mucosal inflammation and result in secondary oral SCC, 19 further studies detailing the interactions between the donor stem cells and the recipients' microenvironments, such as local immunological reactions, may be warranted.
Hematopoietic SCT provides curative therapy for most hematological malignancies. However, we must acknowledge the complications that can occur after this curative procedure, including acute regimen toxicity and GVHD. We have improved the treatment outcome with advances in supportive care and new agents. Our intent is to improve the quality of life and survivorship after curing the original disease. Secondary malignancies are the major cause of late mortality after HSCT and can also impair quality of life. Indeed, much work remains to be carried out to improve this important problem. Identifying a patient at risk and diagnosing the disease early could significantly alleviate this dismal medical condition.
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